

Article



1 2

3

4

5

6

7

8

23

24

# Medical Marijuana Had No Impact on Amphetamine Prescribing in Medicaid

Errien M. Williams<sup>1\*</sup>, Mariam Camara<sup>1,2</sup>, Jessica L. Goldhirsh<sup>1</sup> and Brian J. Piper<sup>1,3</sup>

- Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 2
  - Department of Biology, Pennsylvania State University, Abington, PA
- 3 Center for Pharmacy Innovation and Outcomes, Danville, PA

Correspondence: errienmw15@gmail.com

Abstract: Due to the uncertainty of the health effects medical marijuana poses, states differ in their 9 medical marijuana laws (MML). Long-term effects of marijuana are found to be like attention-defi-10 cit-hyperactive disorder (ADHD). With amphetamines being prescribed to treat ADHD symptoms 11 we hypothesized that amphetamine prescriptions would increase in states implementing MML. The 12 number of amphetamine prescriptions filled quarterly for each state from 2006 to 2021 were calcu-13 lated. States with MML and dispensaries opened before 2020 were examined and states with no 14 MML laws were the control. Prism was utilized to visualize the data and conduct four t-tests be-15 tween the pre and post of MML+ versus MML- states. Three MML+ states were excluded due to 16 limited post-MML data. Among the remaining states, 31 were MML+ and 17 were MML-. No sig-17 nificant differences were found in amphetamine prescribing (p > 0.30). Medical marijuana legaliza-18 tion did not have a statistically significant impact on amphetamine prescribing in Medicaid patients 19 during the analyzed period. Contrary to the hypothesis, the results revealed a non-significant de-20 crease in prescriptions in MML+ states. Further research with recreational cannabis laws or with 21 electronic health records is warranted. 22

# Keywords: Attention Deficit Hyperactivity Disorder; cannabis; stimulant 1. Introduction

Medical marijuana is a controversial topic within political and medical fields [1]. 25 With a history of uncertainty regarding its benefits and its negative effects [2, 3], several 26 states throughout America have yet to espouse unanimity concerning medical marijuana 27 laws (MML). While many states have passed and implemented laws, others believe this 28 matter to be immutable. One study found that long-term cannabis use impaired cogni-29 tive function to varying degrees, which may include emotional control, problem-solving 30 abilities, and executive functioning [4]. Another longitudinal investigation concluded 31 that marijuana use over time impacts short term learning, attention, and inhibition [5]. 32 Many of the effects have similar characteristics to attention-deficit/hyperactivity disor-33 der (ADHD), including inattention, forgetfulness, hyperactivity, and deficits in execu-34 tive cognitive functioning [6, 7]. ADHD affects 5% of children, and 2.5% of adults world-35 wide [8]. ADHD is treated in the U.S. with amphetamines which increase both dopa-36 mine and norepinephrine at the synapse [9]. An increase in these neurotransmitters 37 leads to improvements in executive function and overall reduction of ADHD symptoms 38 [10]. 39

Numerous reports have determined that ADHD is linked to an increased risk of 40 substance use disorder (SUD) [8, 11, 12]. Cannabis is the most commonly used illicit 41 drug among those with ADHD [8]. Further, ADHD can be associated with an increased 42 lifetime use of cannabis use specifically [8]. The risk of marijuana use for ADHD patients 43 is high and can be correlated with an increased risk of using other substances. In turn, 44 Attribution NQTE: This preprint separative research that is substances this the early which is inderested use the salid and in the second s 45 Due to these findings [8, 11, 12, 13], further research is necessary to determine the 46

Citation: To be added by editorial staff during production.

Academic Editor: Firstname Lastname

Received: date Revised: date Accepted: date Published: date



Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons (https://creativecommons.org/license <mark>s/by/4.0/).</mark>

Pharmacoepidemiology 2023, 2, FOR PEER REVIEW

relationship between MML and amphetamine prescriptions. We hypothesized that am-47 phetamine prescriptions would increase after dispensaries opened in states where MML 48was implemented. Specifically, we used Medicaid data to assess the number of ampheta-49 mine prescriptions when corrected for the number of Medicaid and Children's Health 50 Insurance Program (CHIP) enrollees. 51

# 2. Results

40

Three states (Utah, Missouri, and Virginia) were excluded due to not meeting inclu-53 sion criteria. Thirty-one states including Washington D.C. met inclusion criteria and 54 were categorized as MML+ and 17 states were MML-. No relationship was found be-55 tween pre MML+ and post MML+ states (P = 0.2993) nor was there one for pre MML-56 and post MML- states (P = 0.9242, Figure 1). There was also no relationship found in pre 57 MML+ vs pre MML- states (P = 0.3956) and post MML+ vs post MML– states (P= 0.9302, 58 Figure 1). From pre to post in MML- states, there was a -16.5% decline in the slope while 59 pre to post for MML+ states had a -64.0% reduction. Overall, there was no statistically 60 significant difference between MML and amphetamine prescribing from 2006 to 2021 61 between states with or without MML. 62

30 **Rx Slope** 20 10 -/Pre -/Post +/Post +/Pre

Figure 1. Slope of the amphetamine prescriptions (Rx) per 100,000 Medicaid/Children's Health Insurance Program (CHIP) enrollees over time for states with (+) and without (-) medical marijuana laws implemented.

Further examination was completed on the change in slope (Rx over time) for the pre to post periods (Figure 2). Two MML- states, Georgia and Kentucky, had an increase (>+100) and two, Wisconsin and Wyoming, had a decrease (<-100). Similarly, among MML+ states, two increased, New Hampshire and New Mexico, and two decreased, Louisiana and Maine.

63

2

52

64 65 66

67

68

69

70

71

72

#### Pharmacoepidemiology 2023, 2, FOR PEER REVIEW

73

74

75

76

77

78

93




Figure 2. Heat maps demonstrating magnitude of prescription changes over time in amphetamines to Medicaid/Children's Health Insurance Program patients in states with (top) and without (bottom) medical marijuana laws.

#### 3. Discussion

This quasi-experimental report extends upon past research [19] and found that MML 79 implementation and dispensary openings did not significantly impact amphetamine pre-80 scribing. In addition, the hypothesized finding was of an overall increase in prescribing 81 in states which have active medical marijuana dispensaries. However, contrary to our hy-82 pothesis, there was evidence for an average decrease (-64.0%) in prescription slopes over 83 time in states which have dispensaries. In a similar study, researchers tested overall pre-84 scriptions for Medicaid enrollees in areas with MML to determine if prescribing would 85 decrease due to the availability of medical marijuana. They found a decrease in the pre-86 scriptions for pain, depression, nausea, psychosis, and seizures [20]. Another study with 87 similar parameters was conducted and dealt with cannabis use and its effect on opioid 88 and prescription drug consumption. Throughout the study, a slight decrease in this con-89 sumption was evident in locations with marijuana readily available, but there was no sig-90 nificant correlation seen between marijuana and the use opioids and prescription drugs 91 [21]. 92

This report also extends upon prior studies with a Drug Enforcement Administration 94 database which has identified pronounced increases in amphetamine and lisdexamfeta-95 mine distribution over time [22, 23]. The mean slopes in Figure 1 were all greater than 96 zero which indicates that amphetamine prescribing, when corrected for the number of 97

Pharmacoepidemiology 2023, 2, FOR PEER REVIEW

101

117

118

134

enrollees, were increasing. Examination of the pre to post change in slopes (Figure 2) de-98 termined that only two MML- and two MML+ states had decreases (< -100) which again 99 shows the MML had no impact on prescribing at a population level. 100

There were several limitations and caveats which should be considered. The poten-102 tial neurocognitive effects with use of marijuana develop over a long period of time [5]. 103 Studies have linked this long-term use to problems with controlling emotions, executive 104 functioning, and even problem solving [4]. Other studies have linked long term use to 105 problems with attention and short-term learning [5,6]. These potential symptoms mirror 106 patients with ADHD as attentiveness, hyperactivity and problems with executive func-107 tioning are all linked to this disorder as well [6]. A prior report with methadone revealed 108 that four states (Wisconsin, Tennessee, Oregon, and Vermont) accounted for almost two-109 thirds (64.0%) of opioid use disorder prescribing nationally which seems implausible [24]. 110 We cannot discount the possibility of errors (e.g. dual data uploads) in the database [15] 111 so, perhaps, these findings should be verified among those with private insurance. We 112 can not exclude the possibility that some, and perhaps many, medical marijuana patients 113 were previously using marijuana illegally. Future examination of the impact of recrea-114 tional marijuana policies on continued escalation in amphetamine prescribing [Figure 1, 115 22, 23] should be conducted. 116

#### 4. Methods

#### 4.1 Data Sources

Data for the interrupted time series were collected from the Medicaid State Drug 119 Utilization Data (SDUD) from 2006 to 2021 [Supplemental Table 1]. These data were re-120 ported by each state and included information on the drug name, number of prescrip-121 tions filled, and the National Drug Code (NDC) on a quarterly basis [14]. The sum of 122 amphetamine prescriptions filled for each state's quarter, including Washington D.C., 123 for every year was calculated. 124

The number of Medicaid/CHIP enrollees was acquired using Medicaid and the Kai-125 ser Family Foundation (KFF) [Supplemental Table 1] because the Centers for Medicare & 126 Medicaid Services (CMS) began collecting states enrollment data using the Medicaid 127 Budget and Expenditure System (MBES) in 2014 [15]. We used Medicaid to obtain enrol-128 lee data from June 2019 to June 2021. Then for the remaining years, 2006 to 2018, two 129 KFF sources were used to obtain the total number of Medicaid/CHIP enrollees for all 130 states including Washington DC [16, 17]. The enrollee data were recorded for the month 131 of June for each year as the KFF source from 2006 to 2013 only included the mid-year 132 values. 133

# 4.2 Procedures

States were categorized based on presence of a MML and when their first medical 135 marijuana dispensary opened [18]. The dispensary opening date was included per state 136 due to vast differences in the possible lag between the legalization of medical marijuana 137 and its implementation. The states categorized as MML+ had MML and a dispensary 138 open on or prior to 2006 through 2019. Three states with MML and a dispensary opened 139 after 2019 were excluded (Missouri, Utah, Virginia) from the study because our collected 140 SDUD cutoff was 2021. Lastly, states that were MML- served as the comparison. For 141 each state, we divided the sum of prescriptions filled per quarter for each year by the 142 number of Medicaid/CHIP enrollees for the year to determine the prescriptions filled per 143 enrollee. Next, we created pre and post linear regression models for MML+ and MML-144 states. For MML+ states, we plotted twelve quarters pre and post the opening of a 145

Pharmacoepidemiology 2023, 2, FOR PEER REVIEW

5

medical dispensary for all states except those which occurred in 2019. Those states only 146 had eight quarters plotted pre and post dispensary opening due to our collected SDUD 147 stopping at 2021. 148

For MML- states, we determined the date medical marijuana dispensaries opened 149 in states with MML and utilized this as the break-point for the linear regression models 150 [19]. For that calculation, we used the equation 20XX + (x/365.25), with x representing 151 the total number of calendar days a dispensary opened and 365.25 accounting for leap 152 years. There were five states (ME, MT, NV, OR, and WA) that reported only the month 153 and year that dispensaries opened, so we assigned them the 15th of the month. The aver-154 age was calculated to get the estimated date for states with no MML. We proceeded the 155 same way as done for the states with MML in creating the pre and post linear regression 156 models for states with no MML with 12 quarters being used. The resulting values were 157 then adjusted for 100,000 enrollees for the MML+ and MML- states. 158

### 4.3 Statistical Analyses

The mean and standard error of the mean (SEM) were calculated for the slopes of prescriptions over time of the pre and post of MML+ states and MML- states. A slope > 0 was interpreted as increasing prescribing and a slope < 0 as decreasing prescribing. The change in slope (pre vs post) was also determined. Those values were then input in GraphPad Prism. Prism was also used to conduct four t-tests: between 1) pre + vs post + MML, 2) pre – vs post – MML, 3) pre + vs pre – MML, and 4) post + vs post – MML.

Author Contributions: Conceptualization, J.L.G, E.M.W. and B.J.P.,; methodology, E.M.W. and 167 B.J.P.; software, E.M.W.; Formal analysis, E.M.W.; investigation, E.M.W., M.C.; resources, B.J.P.; 168 data curation, ; writing-original draft preparation, E.M.W., writing-review and editing, E.M.W., 169 J.L.G., B.J.P.; visualization, E.M.W.; All authors have read and agreed to the published version of the manuscript."

Funding: This research received no external funding. Software was provided by NIEHS (T32 172 ES007060-31A1). 173

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Geisinger (2021-0313 and ap-175 proved 04-07-2021). 176

Data Availability Statement: Data is available at <link>

Acknowledgments: Thanks to Maria Tian, MBS for technical assistance.

Conflicts of Interest: B.J.P. was (2019-21) part of an osteoarthritis research team supported by Pfizer 179 and Eli Lilly. Other research is currently supported by the Pennsylvania Academic Clinical Research 180Center. Funders had no involvement in this study; in the collection, analyses, or interpretation of 181 data; in the writing of the manuscript; or in the decision to publish the results. The other authors 182 declare no conflict of interest.

#### References

- 1. McKenna GJ. The current status of medical marijuana in the United States. Hawaii J Med Public Health. 2014;73(4):105-108. 185
- 2. National Academies of Sciences, Engineering, and Medicine: The Health Effects of Cannabis and Cannabinoids: The Cur-186 rent State of Evidence and Recommendations for Research. National Academies Press: Washington D.C.; 2017. doi: 187 10.17226/24625 188
- Kendall P: Medical marijuana: the science and the benefits : relieving pain, easing anxiety, improving sleep, plus: the many 3. 189 uses of CBD. Meredith Operations Corporation: New York; 2023. 190
- Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive 191 4. cognitive functions. J Addict Med. 2011;5(1):1-8. doi:10.1097/ADM.0b013e31820c23fa 192
- 5. Ren W, Fishbein D. Prospective, longitudinal study to isolate the impacts of marijuana use on neurocognitive functioning 193 in adolescents. Front Psychiatry. 2023;14:1048791. doi:10.3389/fpsyt.2023.1048791 194

159

160 161

162

163

164

165 166

- 170 171
- 174

177

178

183

184

medRxiv preprint doi: https://doi.org/10.1101/2024.01.27.24301085; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

#### Pharmacoepidemiology 2023, 2, FOR PEER REVIEW

- Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad 195 Med. 2010;122(5):97-109. doi:10.3810/pgm.2010.09.2206 196
- 7. American Psychiatric Association, editor: Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth edition, text revision. American Psychiatric Association Publishing: Washington, DC; 2022.
- 8. Soler Artigas M, Sánchez-Mora C, Rovira P, et al. Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality [published correction appears in Mol Psychiatry. 2021;26(7):3663]. Mol Psychiatry. 2020;25(10):2493-2503. doi:10.1038/s41380-018-0339-3
- 9. Stahl SM: Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge University Press; 2013.
- 10. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018;8(8):CD007813. . doi:10.1002/14651858.CD007813.pub3
- Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328-341.
  doi:10.1016/j.cpr.2011.01.006
- 12. Vold JH, Halmøy A, Chalabianloo F, Pierron MC, Løberg EM, Johansson KA, Fadnes LT. Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study. BMC Psychiatry. 2023;23(1):479. doi:10.1186/s12888-023-04980-w.
- 13. Fergusson DM, Boden JM. Cannabis use and adult ADHD symptoms. Drug Alcohol Depend. 2008;95(1-2):90-96. doi:10.1016/j.drugalcdep.2007.12.012
- 14. State Drug Utilization Data 2020. https://data.medicaid.gov/dataset/cc318bfb-a9b2-55f3-a924-d47376b32ea3.
- 15. Medicaid Enrollment Data Collected Through MBES | Medicaid. https://www.medicaid.gov/medicaid/national-medicaid-chip-program-information/medicaid-chip-enrollment-data/medicaid-enrollment-data-collected-through-mbes/in-dex.html.
- 16. Snyder L, Rudowitz R, Ellis E, Roberts D, Health Management Associates: Medicaid Enrollment: June 2013 Data Snapshot - Appendix A: Table A-1: Total Medicaid Enrollment by State. KFF. Accessed: https://www.kff.org/report-section/medicaid-enrollment-june-2013-data-snapshot-appendix-a-table-a-1-total-medicaid-enrollment-by-state/.
- 17. Smith VK, Health Management Associates, Snyder L, Rudowitz R,: CHIP Enrollment: June 2013 Data Snapshot. KFF. (2014). Accessed: https://www.kff.org/report-section/7642-09-chip-enrollment-june-2013-data-snapshot-appendices/.
- 18. Kaufman DE, Nihal AM, Leppo JD, Staples KM, McCall KL, Piper BJ: Opioid mortality following implementation of medical cannabis programs in the United States. Pharmacopsychiatry. 2021, 54:91–5. 10.1055/a-1353-6509
- 19. Alexander, G. D., Cavanah, L. R., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. Medical cannabis legalization: No contribution to rising stimulant rates. Pharmacopsychiatry. 2023. 56(06): 214-218. DOI: 10.1055/a-2152-7757
- 20. Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs. 2017;36(5):945-951. doi:https://doi.org/10.1377/hlthaff.2016.1135
- Bachhuber MA, Arnsten JH, Cunningham CO, Sohler N. Does medical cannabis use increase or decrease the use of opioid 21. 230 prescription analgesics and other drugs? Journal of Addiction Medicine. 2018;12(4):259-261. 231 doi:https://doi.org/10.1097/adm.000000000000404. 232
- Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, McCall KL. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS One. 2018;13(11):e0206100. doi: 10.1371/journal.pone.0206100.
  234
- Vaddadi SM, Czelatka NJ, Gutierrez BD, Maddineni BC, McCall KL, Piper BJ. Rise, and pronounced regional variation, in methylphenidate, amphetamine, and lisdexamfetamine distribution in the United States. PeerJ. 2021;9:e12619. doi: 236 10.7717/peerj.12619. 237
- Kennalley AL, Fanelli JL, Furst Jr JA., Mynarski NJ, Jarvis MA, Nichols SD, McCall KL, Piper BJ. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic. BMJ Open. 2023. 13(11):e074845. doi: 10.1136/bmjopen-2023-074845.

6

197

198

199

200

201

202

203

204

205

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229